Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound

Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound

The purpose of this study was to evaluate the difference in the effect of coronary plaque regression (as measured by intravascular ultrasound [IVUS] imaging) between cholesterol absorption inhibitor and cholesterol synthesis inhibitor.

Inclusion Criteria:

• Signed written informed consent,
• 30 to 85 years old,
• Plan to undergo PCI and LDL-C >= 100 mg/dL

Exclusion Criteria:

• Familial hypercholesterolemia
• Being treated with Zetia (Ezetimibe)
• Being treated with Fibrates
• Renal insufficiency (serum creatinine >= 2.0 mg/dl)
• Altered hepatic function (serum aspartate aminotransferase or alanine aminotransferase >= 3-folds of standard value in each institute)
• Undergoing hemodialysis or peritoneal dialysis
• Allergic to Lipitor and/or Zetia
• Severe underlying disease
• Lack of decision-making capacity
• Recognized as inadequate by attending doctor